Replimune Group (NASDAQ:REPL) Price Target Raised to $31.00

Replimune Group (NASDAQ:REPL) had its price target lifted by Leerink Partners from $19.00 to $31.00 in a research note published on Thursday,Benzinga reports. Leerink Partners currently has an outperform rating on the stock.

Several other research analysts have also recently commented on the company. JPMorgan Chase & Co. boosted their price target on Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 26th. Wedbush upgraded Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective on the stock in a report on Friday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Replimune Group in a research report on Monday, October 5th. Weiss Ratings cut shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. Finally, Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.33.

Replimune Group Trading Up 1.3%

NASDAQ REPL opened at $17.61 on Thursday. The company’s fifty day simple moving average is $13.58 and its 200-day simple moving average is $9.35. Replimune Group has a 52 week low of $1.50 and a 52 week high of $18.27. The company has a current ratio of 7.11, a quick ratio of 5.23 and a debt-to-equity ratio of 0.59. The stock has a market cap of $1.67 billion, a P/E ratio of -6.31 and a beta of 0.93.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.24. Equities research analysts predict that Replimune Group will post -2.61 EPS for the current fiscal year.

Insider Transactions at Replimune Group

In other Replimune Group news, CFO Emily Hill sold 9,256 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $14.28, for a total value of $132,175.68. Following the completion of the sale, the chief financial officer directly owned 215,852 shares in the company, valued at $3,082,366.56. This represents a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $510,252.77. Following the transaction, the chief executive officer directly owned 708,151 shares of the company’s stock, valued at approximately $9,184,718.47. The trade was a 5.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 79,124 shares of company stock worth $1,038,364 in the last three months. 5.40% of the stock is currently owned by company insiders.

Institutional Trading of Replimune Group

A number of large investors have recently added to or reduced their stakes in REPL. BlackRock Inc. acquired a new position in Replimune Group in the 2nd quarter worth about $99,171,000. Opaleye Management Inc. acquired a new stake in shares of Replimune Group during the 2nd quarter valued at about $15,332,000. EcoR1 Capital LLC acquired a new stake in shares of Replimune Group during the 1st quarter valued at about $7,650,000. ADAR1 Capital Management LLC acquired a new stake in shares of Replimune Group during the 2nd quarter valued at about $7,260,000. Finally, Jefferies Financial Group Inc. bought a new stake in shares of Replimune Group in the 2nd quarter valued at approximately $5,485,000. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.